Close Menu
Home › Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

Myriad Genetics, AstraZeneca, Merck Expand BRCA CDx Collaboration

Apr 04, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Myriad Genetics announced today it has expanded its collaboration with AstraZeneca and Merck to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer (mCRPC) and germline BRCA mutations who are likely to respond to olaparip (Lynparza).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
18
Featured Webinar

Simultaneous Single-Cell DNA and Protein Sequencing in AML Samples

Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. FDA Clears NantHealth Tumor-Normal Whole-Exome Test

  2. AMP Attendees Reflect on Uptake of Tumor Mutational Burden Amid Validation, Utility Questions

    Premium

  3. Melanoma Patients See Magnified Benefit From Targeted Treatment Combo in Five-Year Outcomes Data

  4. European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

  5. Bristol-Myers, PathAI Show Artificial Intelligence Is on Par With Manual PD-L1 Scoring

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.